Cellebrite DI Ltd. $CLBT Shares Sold by Greenhaven Road Investment Management L.P.

Greenhaven Road Investment Management L.P. reduced its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 3.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,599,937 shares of the company’s stock after selling 53,110 shares during the quarter. Cellebrite DI accounts for about 4.8% of Greenhaven Road Investment Management L.P.’s holdings, making the stock its 4th biggest position. Greenhaven Road Investment Management L.P. owned approximately 0.67% of Cellebrite DI worth $28,847,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in CLBT. Advisory Services Network LLC purchased a new position in Cellebrite DI during the third quarter worth about $40,000. CWM LLC boosted its holdings in Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares during the last quarter. First Horizon Corp boosted its holdings in Cellebrite DI by 421.8% during the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after purchasing an additional 2,337 shares during the last quarter. Vestcor Inc purchased a new position in Cellebrite DI during the third quarter worth about $70,000. Finally, PNC Financial Services Group Inc. boosted its holdings in Cellebrite DI by 114.5% during the third quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock worth $83,000 after purchasing an additional 2,403 shares during the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

CLBT opened at $12.84 on Friday. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of 45.86, a PEG ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a twelve month low of $11.02 and a twelve month high of $19.98. The company’s 50-day moving average price is $13.23 and its two-hundred day moving average price is $15.05.

Wall Street Analysts Forecast Growth

CLBT has been the topic of several analyst reports. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. DA Davidson initiated coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 price target on the stock. Needham & Company LLC cut their price target on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Insiders Place Their Bets

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. The trade was a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 13,269 shares of company stock valued at $169,592 in the last 90 days. 5.70% of the stock is owned by insiders.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.